Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1)

Luca Miele, Alessia Perna, Marianxhela Dajko, Maria A. Zocco, Antonio De Magistris, Tommaso F. Nicoletti, Marco Biolato, Giuseppe Marrone, Antonio Liguori, Daria Maccora, Venanzio Valenza, Salvatore Rossi, Vittorio Riso, Daniele Di Natale, Antonio Gasbarrini, Antonio Grieco, Gabriella Silvestri

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Myotonic dystrophy type 1 (DM1) is a rare inherited neuromuscular disease associated with insulin resistance, and its association with metabolically associated fatty liver disease (MAFLD) has never been explored in prospective studies. The aim of this study was to assess the clinical features of MAFLD in DM1 patients. Methods: We investigated the prevalence and the diagnostic features of MAFLD in a cohort of 29 outpatient fully characterized DM1 patients; afterward, we compared the selected cohort of DM1-MAFLD individuals with a propensity-matched cohort of non-DM1-MAFLD Results: 13/29 (44.83%) DM1 patients received a clinical diagnosis of MAFLD. Compared to DM1 patients with normal liver, DM1-MAFLD individuals showed a higher male prevalence (p = 0.008), BMI (p = 0.014), HOMA score (p = 0.012), and GGT levels (p = 0.050). The statistical comparison showed that the DM1-MAFLD group had a more severe MAFLD according to the FIB4 score than non-DM1-MAFLD patients. This association of a more severe form of liver disease with DM1 remained significant after logistic regression analysis (OR: 6.12, 95% CI 1.44- 26.55).

Original languageEnglish
Pages (from-to)1451-1457
Number of pages7
JournalDigestive and Liver Disease
Volume53
Issue number11
DOIs
Publication statusPublished - Nov 2021

Keywords

  • Liver tests
  • MAFLD
  • Myotonic dystrophy
  • NAFLD
  • NASH
  • Steinert's disease

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1)'. Together they form a unique fingerprint.

Cite this